Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC (disitamab vedotin) + toripalimab for HER2-positive locally advanced or metastatic scrotal extramammary Paget's disease
ChiCTR2500095968Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin and toripalimab in extramammary Paget disease (EMPD), sponsored by Fujian Medical University Union Hospital. Primary endpoints: Area of the largest lesion on scrotal skin, Longest diameter of metastatic lymph nodes and 7 more. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
disitamab vedotintoripalimab
03
Conditions
extramammary Paget disease (EMPD)
Beyond the preview
Go deeper on ChiCTR2500095968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095968.